KR20170021140A - Combination composition for treatment of diarrhea in calf - Google Patents
Combination composition for treatment of diarrhea in calf Download PDFInfo
- Publication number
- KR20170021140A KR20170021140A KR1020150115572A KR20150115572A KR20170021140A KR 20170021140 A KR20170021140 A KR 20170021140A KR 1020150115572 A KR1020150115572 A KR 1020150115572A KR 20150115572 A KR20150115572 A KR 20150115572A KR 20170021140 A KR20170021140 A KR 20170021140A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- present
- diarrhea
- sulfamethoxazole
- combination
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 71
- 244000309466 calf Species 0.000 title claims description 31
- 229960005404 sulfamethoxazole Drugs 0.000 claims abstract description 25
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960002385 streptomycin sulfate Drugs 0.000 claims abstract description 23
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims abstract description 23
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 22
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 22
- 229960001082 trimethoprim Drugs 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 8
- 241000411851 herbal medicine Species 0.000 claims description 25
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 12
- 229940107700 pyruvic acid Drugs 0.000 claims description 10
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 9
- 229960005091 chloramphenicol Drugs 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 241000711573 Coronaviridae Species 0.000 claims description 4
- 244000000010 microbial pathogen Species 0.000 claims description 4
- 241000702670 Rotavirus Species 0.000 claims description 3
- 241000238421 Arthropoda Species 0.000 claims description 2
- 241000224483 Coccidia Species 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 1
- UIERETOOQGIECD-ARJAWSKDSA-N angelic acid group Chemical group C(\C(\C)=C/C)(=O)O UIERETOOQGIECD-ARJAWSKDSA-N 0.000 claims 1
- 244000144972 livestock Species 0.000 abstract description 32
- 239000002131 composite material Substances 0.000 abstract description 31
- 239000003795 chemical substances by application Substances 0.000 abstract description 20
- 230000000845 anti-microbial effect Effects 0.000 abstract description 14
- 230000000840 anti-viral effect Effects 0.000 abstract description 12
- 239000003814 drug Substances 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 239000000843 powder Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 241000283690 Bos taurus Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 6
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 6
- 229940010454 licorice Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 240000004670 Glycyrrhiza echinata Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 229940030225 antihemorrhagics Drugs 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 2
- 241001105098 Angelica keiskei Species 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000711443 Bovine coronavirus Species 0.000 description 2
- 241000702673 Bovine rotavirus Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- -1 compounds streptomycin sulfate Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940006995 sulfamethoxazole and trimethoprim Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 238000002768 Kirby-Bauer method Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940038217 chloramphenicol 500 mg Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000019516 cod Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 235000020704 flaxseed extract Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000027909 hemorrhagic diarrhea Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 가축설사 치료용 복합제 조성물에 관한 것으로, 보다 상세하게는 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산을 포함하는, 가축설사 치료용 복합제 조성물, 및 이를 이용한 가축설사 치료방법에 관한 것이다.
The present invention relates to a composition for treating diarrhea in a domestic animal, and more particularly to a composition for treating diarrhea in a domestic animal including streptomycin sulfate, sulfamethoxazole, trimethoprim and tranexamic acid, ≪ / RTI >
최근 들어 가축사육이 집약화되면서 병원성 미생물에 의해 집단적으로 감염되는 사례가 빈발하고 있으며, 감염된 가축 대부분은 설사 및 혈변 등의 질병 증상을 나타내는데, 생후 1개월 이내의 가축의 경우, 감염으로 인해 설사 등이 발생하게 되면 생명에 치명적이거나 가축의 성장에 큰 영향을 미칠 수 있다.In recent years, infested livestock has been collectively infected by pathogenic microorganisms as a result of intensification of livestock breeding. Most of the infected livestock shows symptoms of diarrhea and bloody diseases. In case of livestock within one month after birth, If they occur, they can be life-threatening or have a large impact on the growth of livestock.
특히, 소의 설사질환 중 대표적 질병인 소바이러스 감염증은 소화관 점막의 궤양과 설사, 호흡기 병변 등을 유발하고, 모든 연령의 소에서 감염되나 어린 송아지에 감수성이 더 높으며, 주로 겨울에서 봄 사이에 많이 발병하는 질병으로서, 고열, 점액성이고 혈액성의 심한 설사, 백혈구감소증 등 식욕절폐, 유량감소, 기침, 호흡곤란, 콧물, 탈수에 의한 폐사 등의 증상을 나타낸다. 임신 초기의 암소에 감염시 태반으로 인한 유산, 흑자 및 사산도 일어나며 신생송아지는 운동실조 및 허약증세도 일으킨다.In particular, the bovine viral infectious disease, which is a representative disease of bovine diarrheal disease, causes gastric ulcer, diarrhea, respiratory lesion, etc., and is susceptible to infestation at all ages but is more susceptible to young calves. It is a disease of high fever, mucinous, severe diarrhea with hemorrhagic diarrhea, leukopenia, decreased appetite, decreased flow, coughing, dyspnea, runny nose, and dehydration. The placenta-induced abortion, surplus, and stillbirth also occur when the cow is infected in the early stages of pregnancy, and the new calf also causes ataxia and weakness.
또한, 소 로타 바이러스(Bovine rotavirus; BRV) 감염증은 갓 태어난 어린 송아지에 감염시 설사를 유발시키며 가장 피해가 심한 소화기 질병 중 하나로 주로 생후 1주령 미만의 어린 송아지에 감염되면 높은 폐사율을 나타내고 회복되더라도 비육능력이 떨어진다.In addition, bovine rotavirus (BRV) infections cause diarrhea when infected with newborn calves, and are one of the most severely harmful digestive diseases. When infected with young calves under the age of 1 week, they show high mortality, The ability drops.
또한, 코로나 바이러스(Bovine coronavirus; BCV) 감염증은 심한 경우 유량이 감소하며 사료효율의 저하 및 육우의 증체율 감소가 일어난다. 어린 송아지에서는 발생율이 높으며 유행성폐렴의 1차 원인체이기도 하다. 주로 소장 및 결장에 병변이 생기며 특히 융모의 심한 위축, 융합, 탈락 등이 관찰되고 흡수부전으로 인한 노란색 수양성 설사와 심한 탈수 등이 일어나며, 쇠약해지고 무기력을 보이다 저혈량증으로 폐사하기도 하며, 어린 송아지에 감수성이 높은 중요한 질병 중 하나이다.In addition, coronavirus (Bovine coronavirus (BCV) infectious disease, in severe cases, decreases the flow rate, decreases feed efficiency and decreases the rate of growth of beef cattle. In young calves, the incidence is high and is the primary cause of pneumonia. There are lesions in the small intestine and colon, especially severe atrophy of the villi, fusion and dislocation. Yellow watery diarrhea due to absorption failure and severe dehydration occur, and they are weakened, weakened, It is one of the most important diseases susceptible to calves.
또한, 병원성 대장균(Escherichia coli)은 장관 감염에 의해 발생되며 송아지의 경우 설사병, 위축 및 폐사를 주증으로 하고 포유 및 이유 송아지에서 많이 발생하며 집약적인 집단관리에 의한 스트레스가 주원인으로 알려져 있다. In addition, Escherichia coli is caused by intestinal infections. In calves, diarrhea, atrophy and dysentery are the main causes, and it is known that stress is caused by intensive group management which occurs frequently in mammals and calves.
이러한 가축의 설사질환을 치료하기 위한 치료제들이 개발되고 있으며, 양약뿐만 아니라 생약(천연물 추출물)도 다양하게 개발되고 있으며, 그 예로서 한국특허공개 제10-2004-0106673호(가축의 설사 및 탈수 치료용 조성물 및 이를 이용한치료방법), 한국등록특허 제10-1067536호(송아지의 설사치료용 조성물), 한국등록특허 제10-0920713호(설사 예방 또는 치료용 조성물) 등이 공지되어 있다. Therapeutic agents for treating diarrheal diseases of such livestock have been developed and various medicines (natural extracts) as well as medicines have been developed. For example, Korean Patent Publication No. 10-2004-0106673 (Diarrhea and dehydration of livestock Korean Patent No. 10-1067536 (composition for treating diarrhea in calves), Korean Patent No. 10-0920713 (composition for preventing or treating diarrhea), and the like are known.
또한, 가축의 질병, 특히 설사질환을 치료하기 위한 항균제 및 항생제들은 많이 개발되었으나 두 종류의 유효 성분을 배합하였을 때 상승 효과가 나타나는 복합제의 개발은 많이 개발되지 않았다. 대부분의 복합제 조성물은 단일 제제와는 달리 유효 성분의 배합에 따른 상승 효과를 시험하는데 장시간의 기일과 자금을 필요로 하므로 복합 제제 조성물에 대한 연구는 많이 이루어지지 않은 것이 현실이다.
In addition, many antimicrobial agents and antibiotics for treating diseases of livestock, especially diarrheal diseases have been developed, but development of a complex agent having a synergistic effect when two kinds of active ingredients are mixed has not been developed much. Most of the compositions of the present invention do not have much research on the combination preparation compositions because they require a long period of time and funds to test the synergistic effect of the active ingredients.
이에, 본 발명자는 가축의 설사질환, 특히 소의 설사질환에 효과적인 치료제를 개발하던 중, 특정 항생제, 항균제 및 지혈제, 구체적으로 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산을 일정 조성비로 포함하는 복합제 조성물이 각각을 단독으로 사용했을 때에 비해, 항균 및 항바이러스 활성이 증대되어 가축의 설사질환에 특별히 효과적임을 발견함으로써, 본 발명을 완성하였다.
Accordingly, the inventors of the present invention have developed a therapeutic agent effective against diarrheal diseases of livestock, particularly diarrheal diseases of cattle, and have found that a specific antibiotic, an antibacterial agent and a hemostatic agent, specifically streptomycin sulfate, sulfamethoxazole, trimethoprim and tranexamic acid, The present inventors have completed the present invention by finding that the composition of the present invention is particularly effective for the diarrheal disease of livestock by increasing antimicrobial and antiviral activity as compared with the case where each of them is used alone.
본 발명의 목적은 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산을 포함하여 증진된 항균 및 항바이러스 활성을 나타내는 가축 설사질환 치료용 복합제 조성물을 제공하는 것이다.It is an object of the present invention to provide a combination composition for the treatment of livestock diarrheal disease which exhibits enhanced antibacterial and antiviral activity including streptomycin sulfate, sulfamethoxazole, trimethoprim and tranexamic acid.
본 발명의 또 다른 목적은 상기 복합제 조성물을 투여하는 단계를 포함하는 가축 설사질환의 치료방법을 제공하는 것이다.
Yet another object of the present invention is to provide a method for treating a diarrheal disease of a domestic animal comprising the step of administering the combination composition.
본 발명의 일 측면에 따르면, 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산을 포함하는 가축 설사질환 치료용 복합제 조성물이 제공된다.According to one aspect of the present invention, there is provided a combination composition for treating livestock diarrhea disease comprising streptomycin sulfate, sulfamethoxazole, trimethoprim, and tranexamic acid.
본 발명에서 상기 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산은 8~12 : 4~8 : 1~2 : 2~3의 중량비로 포함될 수 있다.In the present invention, the streptomycin sulfate, sulfamethoxazole, trimethoprim and tranexamic acid may be contained at a weight ratio of 8-12: 4 to 8: 1 to 2: 2 to 3.
본 발명에서 상기 조성물은 클로람페니콜을 추가로 포함할 수 있다.In the present invention, the composition may further comprise chloramphenicol.
본 발명에서 상기 조성물은 궁귀교애탕, 향사평위산 및 평위산 중에서 선택되는 하나 이상의 한방처방생약을 추가로 포함할 수 있다.In the present invention, the composition may further comprise at least one herbal medicine selected from Oriental herb tea, oriental pyruvic acid and pyruvic acid.
본 발명에서 상기 가축은 소, 돼지, 닭, 오리, 양으로 구성된 군으로부터 선택될 수 있다.In the present invention, the livestock may be selected from the group consisting of cattle, pigs, chickens, ducks, and sheep.
본 발명에서 상기 가축 설사질환은 특히 송아지 설사증일 수 있다. 이때 상기 송아지 설사증은 로타 바이러스, 코로나 바이러스, 대장균 및 콕시듐으로 이루어진 군으로부터 선택되는 하나 이상의 병원성 미생물의 감염에 의해 유발된 것일 수 있다.In the present invention, the livestock diarrheal disease may be calf diarrhea in particular. Wherein the calf diarrhea may be caused by infection of one or more pathogenic microorganisms selected from the group consisting of rotavirus, coronavirus, E. coli and coccidum.
본 발명에서 상기 조성물은 약제학적 조성물, 특히 경구 투여용 약제학적 조성물일 수 있다.In the present invention, the composition may be a pharmaceutical composition, particularly a pharmaceutical composition for oral administration.
본 발명의 다른 측면에 따르면, 상기 본 발명의 복합제 조성물을 투여하는 단계를 포함하는 가축 설사질환의 치료방법이 제공된다.
According to another aspect of the present invention, there is provided a method of treating livestock diarrheal disease comprising administering the combination composition of the present invention.
본 발명에 따른 복합제 조성물은 클로람페니콜, 설파메톡사졸 및 트리메토프림을 동시에 포함함으로써, 단독 제제에 비해 항균 및 항바이러스 활성이 현저히 증대되어, 광범위한 설사질환 치료에 효과적인 바, 가축의 설사질환 치료제 제조에 유용하게 이용될 수 있다.
The combination composition according to the present invention simultaneously contains chloramphenicol, sulfamethoxazole and trimethoprim. Thus, the antimicrobial and antiviral activity is remarkably increased compared to a single agent, and is effective for the treatment of a wide range of diarrheal diseases. Can be usefully used.
도 1은 본 발명의 일 실시예에 따른 복합제 조성물을 송아지 백리 설사증에 적용한 경우 치료 경과를 나타내는 성적서이다.
도 2는 본 발명에 대한 실험한 결과를 제공한 의사의 사업자등록증이다. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a report showing the progress of treatment of a combination composition according to an embodiment of the present invention when applied to calf leprae diarrhea.
FIG. 2 is a business registration card of a doctor who provided the results of an experiment on the present invention.
하나의 양태로서, 본 발명은 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산을 포함하는 가축 설사질환 치료용 복합제 조성물에 관한 것이다.In one aspect, the present invention relates to a combination composition for treating livestock diarrhea disease comprising streptomycin sulfate, sulfamethoxazole, trimethoprim, and tranexamic acid.
이하, 본 발명의 구성을 더욱 상세히 설명한다.Hereinafter, the configuration of the present invention will be described in more detail.
본 발명의 조성물은 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산을 복합제 형태로 동시에 포함하여 가축 설사질환의 치료 및 예방에 탁월한 효과를 나타냄을 특징으로 한다. The composition of the present invention is characterized by exhibiting an excellent effect in the treatment and prevention of diarrheal disease of livestock by simultaneously including streptomycin sulfate, sulfamethoxazole, trimethoprim and tranexamic acid in the form of a combination.
본 발명에서 황산스트렙토마이신은 대표적인 항생제의 일종으로서, 미생물이 특정 활성 단백질을 합성할 수 있는 능력을 저해함으로써 항균활성을 나타내며, 광범위한 병원미생물에 적용할 수 있는 것으로 알려져 있다. In the present invention, streptomycin sulfate is a typical antibiotic. It is known that microorganisms exhibit antibacterial activity by inhibiting their ability to synthesize specific active proteins, and are applicable to a wide range of hospital microorganisms.
본 발명에서 설파메톡사졸은 설파계 항균제의 일종으로, 화학명 "4-아미노-N-(5-메틸아이속사졸-3-일)-벤젠설폰아마이드(4-amino-N-(5-methylisoxazol-3-yl)-benzenesulfonamide)"이다. 설파메톡사졸은 세균의 엽산합성을 가역적으로 억제하여 정균작용을 나타내며, 다양한 세균성 감염증 치료에 이용되는 것으로 알려져 있다. In the present invention, sulfamethoxazole is a kind of sulfamide-based antimicrobial agent, which is a compound having a chemical name of 4-amino-N- (5-methylisoxazol-3-yl) 3-yl) -benzenesulfonamide) ". Sulfamethoxazole reversibly inhibits bacterial folate synthesis, exhibits bacteriostatic activity, and is known to be used in the treatment of various bacterial infections.
본 발명에서 트리메토프림은 설파메톡사졸과 같이 세균의 엽산합성을 억제함으로써 항균작용을 하는 물질로 알려져 있으며, 그 화학명은 "5-(3,4,5-트리메톡시벤질)피리미딘-2,4-디아민 (5-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine)"이다. In the present invention, trimethoprim is known as a substance that has antimicrobial activity by inhibiting the synthesis of folate of bacteria such as sulfamethoxazole, and its chemical name is "5- (3,4,5-trimethoxybenzyl) pyrimidin- Diaminone (5- (3,4,5-trimethoxybenzyl) pyrimidine-2,4-diamine).
본 발명에서 상기 트라넥사민산은 지혈제의 일종으로 주로 출혈성 질환이나 수술후 출혈 등에 적용되는 약물로 알려져 있다.
In the present invention, the above-mentioned tranexamic acid is a kind of hemostatic agent and is known as a drug mainly applied to hemorrhagic diseases or post-operative bleeding.
본 발명에서, 화합물인 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산의 각 화합물은 공지의 합성방법을 통해 직접 합성시켜 사용하거나, 시판되는 것을 이용할 수 있다. 또한, 본 발명의 상기 화합물은 유효한 항균 활성 및 항바이러스 활성을 잃지 않는 범위에서, 화합물의 약제학적으로 허용되는 염 또는 화합물의 유도체 형태로 이용가능하며, 상기 화합물의 염 또는 유도체는 당해 기술분야에서 통상적인 방법으로 제조될 수 있다. In the present invention, each compound of the compounds streptomycin sulfate, sulfamethoxazole, trimethoprim, and tranexamic acid may be directly synthesized through known synthesis methods, or commercially available ones may be used. Further, the compound of the present invention can be used in the form of a pharmaceutically acceptable salt or a derivative of the compound, so long as it does not lose the antimicrobial activity and the antiviral activity, and the salt or derivative of the compound can be used in the art Can be prepared by conventional methods.
본 발명에서 상기 화합물의 "약제학적으로 허용되는 염”이란 약리학적 또는 생리학적으로 허용되는 무기산, 유기산 및 염기로부터 유도된 염을 의미한다. 적합한 산의 예로는 염산, 브롬산, 황산, 질산, 과염소산, 푸마르산, 말레산, 인산, 글리콜산, 락트산, 살리실산, 숙신산, 톨루엔-p-설폰산, 타르타르산, 아세트산, 시트르산, 메탄설폰산, 포름산, 벤조산, 말론산, 나프탈렌-2-설폰산, 벤젠설폰산 등을 포함할 수 있고, 적합한 염기로부터 유도된 염은 알칼리 금속, 예들 들어, 나트륨, 알칼리토금속, 예들 들어, 마그네슘, 암모늄 등을 포함할 수 있으나, 이에 제한되는 것은 아니다.
The term "pharmaceutically acceptable salt " of the compound in the present invention means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases. Examples of suitable acids include hydrochloric acid, hydrobromic acid, sulfuric acid, But are not limited to, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene- And salts derived from suitable bases may include, but are not limited to, alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium, and the like.
본 발명의 조성물은 항생제인 황산스트렙토마이신, 항균제인 설파메톡사졸 및 트리메토프림, 지혈제인 트라넥사민산을 복합제 형태로 동시에 포함하여 증진된 항균 활성 및 항바이러스 활성을 가짐을 특징으로 한다. 다시 말해, 본 발명의 조성물은 세균성 병원균이나 바이러스 또는 진균에 대해 증진된 항균 및 항바이러스 활성을 나타내어, 가축 설사질환의 치료 및 예방에 탁월한 효과를 낸다. The composition of the present invention is characterized by having antimicrobial activity and antiviral activity simultaneously including antibiotic sulfate streptomycin, antimicrobial sulfamethoxazole and trimethoprim, and hemostatic agent tranexamic acid in combination. In other words, the composition of the present invention exhibits enhanced antimicrobial and antiviral activity against bacterial pathogens, viruses or fungi, and exerts an excellent effect in the treatment and prevention of livestock diarrheal disease.
또한, 본 발명의 조성물은 상기한 구성성분의 혼합 비율을 조정하여 병원성 균주 및 바이러스에 대한 항균, 항바이러스 활성을 더욱 증대시킬 수 있다. 본 발명의 조성물에 포함되는 상기한 각 구성성분은 건조분말 중량을 기준으로, 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산이 8~12 : 4~8 : 1~2 : 2~3의 중량비로 포함되는 것이 바람직하며, 가장 바람직하게는 10 : 6 : 1.2 : 2.5의 중량비로 포함될 수 있다. 본 발명의 조성물이 상기와 같은 적정 혼합 비율의 범위를 넘게 되면, 증진된 항균 및 항바이러스 활성을 가질 수 없거나, 약물 과다 사용으로 인해 내부 장기, 특히 소화기에 독성을 나타내는 등의 부작용을 일으킬 수 있다. In addition, the composition of the present invention can further increase antimicrobial and antiviral activity against pathogenic strains and viruses by adjusting the mixing ratio of the above components. Each of the above-mentioned components contained in the composition of the present invention may be used in an amount of from 8 to 12: 4 to 8: 1 to 2: 2 to 4: 1, based on the dry powder weight, of streptomycin sulfate, sulfamethoxazole, trimethoprim, 3, and most preferably in a weight ratio of 10: 6: 1.2: 2.5. If the composition of the present invention exceeds the appropriate mixing ratio as described above, it can not have enhanced antimicrobial and antiviral activity, or it may cause adverse effects such as toxicity to internal organs, especially digestive system, due to excessive drug use .
본 발명의 가축 설사질환 치료용 복합제 조성물은 항생제의 일종인 클로람페니콜을 추가로 포함할 수 있다. 클로람페니콜은 방선균 등에 의해 얻은 항생물질로서 화학합성으로도 제조가 가능하며, 그람양성균, 음성균 리케차, 크리미디아에 정균적으로 작용하는 것으로 알려져 잇다. 본 발명의 조성물이 클로람페니콜을 추가로 포함하는 경우, 항균 및 항바이러스 활성이 더욱 증진될 수 있다. 본 발명의 조성물에 클로람페니콜이 포함되는 경우, 건조분말 중량을 기준으로, 황산스트렙토마이신 100중량부에 대해 40~70중량부로 포함될 수 있고, 바람직하게는 45~55중량부로 포함될 수 있다. 이러한 함량범위에서 독성이나 부작용 없이 항균 및 항바이러스 활성을 증진시킬 수 있다.The composition for treating diarrheal disease of the present invention may further comprise chloramphenicol, which is a kind of antibiotic. Chloramphenicol is an antibiotic substance obtained by actinomycetes and the like, and it can be produced by chemical synthesis. It is known that chloramphenicol acts as a bacterium to gram-positive bacteria, negative bacteria such as Rickettsia and Crimeida. If the composition of the present invention further comprises chloramphenicol, the antibacterial and antiviral activity may be further enhanced. When chloramphenicol is contained in the composition of the present invention, it may be contained in an amount of 40 to 70 parts by weight, preferably 45 to 55 parts by weight, based on 100 parts by weight of streptomycin sulfate, based on the dry powder weight. Within this range of content, antimicrobial and antiviral activity can be enhanced without toxicity or side effects.
또한, 상기 조성물은 통상적인 설사질환에 이용되는 공지의 항균제, 항생제 및 항염증제를 추가로 포함할 수 있다.
In addition, the composition may further include known antimicrobial agents, antibiotics and anti-inflammatory agents used for conventional diarrheal diseases.
본 발명의 가축 설사질환 치료용 복합제 조성물은 상술한 황산스트렙토마이신, 설파메톡사졸, 트리메토프림, 트라넥사민산의 양약 성분 외에 한방처방생약을 추가로 포함할 수 있다. 구체적으로 상기 조성물은 궁귀교애탕, 향사평위산 및 평위산 중 하나 이상의 한방처방생약을 추가로 포함할 수 있다. 이러한 한방처방생약을 추가로 포함하는 경우 상기 양약의 항균 및 항바이러스 활성에 의한 질환 치료 효과 외에 한방학적 측면에서 가축 몸속의 기운을 복돋고 양약으로 인해 차게 된 속을 따듯하게 하여 소화기능을 향상시켜 질환 치료율을 더욱 높일 수 있다. 특히 회복 속도가 빨라지고 병의 재발율이 현저하게 줄어들게 되는 효과가 있다.The composition for treating diarrheal disease according to the present invention may further comprise a herbal medicine other than the herbal ingredients of streptomycin sulfate, sulfamethoxazole, trimethoprim, and tranexamic acid as described above. Specifically, the composition may further comprise one or more prescription herbal medicines, at least one of royal jellyfish, oriental pyruvic acid and pyruvic acid. In addition to the effect of treating the disease caused by the antibacterial and antiviral activity of the above-mentioned herbal medicine, when the herbal medicine containing the herbal medicine is additionally contained, it enhances the energy of the livestock body in the aspect of oriental medicine, The disease cure rate can be further increased. In particular, the recovery rate is faster and the recurrence rate of the disease is remarkably reduced.
상기 궁귀교애탕은 빈혈 개선 및 지혈 작용을 하는 것으로 알려져 있으며, 그 조성은 천궁, 당귀, 애엽, 작약, 지황, 감초 및 아교를 포함할 수 있다. 상기 각성분의 조성비는 당업계에 공지된 방법을 이용할 수 있으며, 예를 들어 천궁 4.0 : 당귀 6.0 : 애엽 6.0 : 작약 8.0 : 지황 8.0 : 감초 4.0 : 아교 4.0 의 조성비로 이용할 수 있다. The arthropods are known to have anemia improvement and hemostasis, and their composition may include astragalus, angelica, rhinoceros, peony, rhubarb, licorice and glue. For example, the composition ratio of each component can be used in the composition ratio of Angelica keiskei 4.0: Angelica keiskei 6.0: Lyophilized 6.0: Peony powder 8.0: Gypsum 8.0: Licorice 4.0: Glue 4.0.
상기 향사평위산 및 평위산은 소화장애가 있는 경우 처방하는 약으로서, 가축의 생체, 특히 위장을 따듯하게 하여 소화를 돕고 가스를 제거하는 역할을 한다. 상기 향사평위산은 창출, 진피, 향부자, 지실, 곽향, 후박, 사인, 목향, 감초 및 생강을 함유할 수 있다. 상기 각 성분의 조성비는 당업계에 공지된 조성을 이용할 수 있고, 예를 들어 창출 4.0 : 진피 2.0 : 향부자 2.0 : 지실 1.5 : 곽향 1.5 : 후박 1.5 : 사인 1.5 : 목향 1.0 : 감초 1.0 : 생강 0.6 의 조성비로 이용할 수 있다.Pyroxin and pyruvic acid are drugs to prescribe when there is digestive disturbance. They help digestion and remove the gas by warming the living body of the livestock, especially the stomach. The flavored plain acid may contain creams, dandruffs, herbal extracts, flaxseed extracts, horseradish, cod, sesame, licorice and ginger. The composition ratio of each component can be a composition known in the art, for example, Creation 4.0: Dermis 2.0: Fructus 2.0: Starch 1.5: Welsh 1.5: Grass 1.5: Sine 1.5: .
또한, 상기 평위산은 창출, 후박, 진피, 생강, 대추 및 감초를 함유할 수 있다. 상기 각 성분의 조성비는 당업계에 공지된 조성을 이용할 수 있고, 예를 들어 창출 4.0 : 후박 3.0 : 진피 3.0 : 생강 2.0 : 대추 2.0 : 감초 1.0 의 조성비로 이용할 수 있다. In addition, the pyeonyangsan may contain Creation, Chinese cabbage, dermis, ginger, jujube and licorice. The composition ratio of each component can be used in a composition known in the art. For example, it can be used in a composition ratio of Creation 4.0: Grass 3.0: Derm 3.0: Ginger 2.0: Jujube 2.0: Licorice 1.0.
상기 평위산 및 향사평위산의 구성성분인 진피는 담즙분비를 촉진하여 소화관운동능을 강화하며, 후박은 항균작용을 하여 장염을 개선하고 복통에 진경작용을 하는 것으로 알려져 있다. 창출은 소화관점막의 부종을 완화하여 구역과 구토를 개선하고, 감초는 위염증상을 완화하는 것으로 알려져 있다.It is known that the dermis, which is a constituent of the pisan acid and the perilla flavic acid, promotes bile secretion and strengthens the gastrointestinal motility. It is known that alleviating swelling of the mucous membrane of the digestive tract improves the area and vomiting, and licorice relieves the symptoms of gastritis.
상기 궁귀교애탕, 향사평위산 및 평위산의 한방처방생약은 각각 시판되는 한방처방생약을 입수하여 사용하거나, 당업계에 공지된 추출방법으로 제조하여 사용할 수 있다. 바람직하게는 고방 제조법에 따라 제조된 건조 과립분말 형태로 제조된 것을 사용할 수 있다. 건조 과립분말 형태의 한방처방생약을 사용하는 경우 생약의 1회 사용량은 각각 3~10g 일 수 있고, 바람직하게는 4~6g, 더욱 바람직하게는 5g 정도이다. The herbal medicine herbal medicine, oriental herbal medicine and pyeongyang san herbal medicine can be obtained by using commercially available oriental herbal medicine or can be manufactured by using an extraction method known in the art. Preferably, those prepared in the form of dry granular powder prepared according to the high-temperature preparation method may be used. When the oriental herbal medicine in the form of dry granular powder is used, the dosage of herbal medicine may be 3 to 10 g, preferably 4 to 6 g, and more preferably 5 g.
본 발명의 조성물은 황산스트렙토마이신, 설파메톡사졸, 트리메토프림, 트라넥사민산, 클로람페니콜, 궁귀교애탕, 향사평위산 및 평위산을 모두 포함할 수 있다. 이러한 경우 가축 설사칠환 치료시 치료 속도가 빠르고 완치율이 100%에 가까울 정도로 치료 효과가 높으며, 병이 재발하지 않는 효과가 있다. 본 발명의 조성물이 궁귀교애탕, 향사평위산 및 평위산의 한방처방생약 세가지를 모두 포함하는 경우 그 조성은 0.5~1.5 : 0.5~1.5 : 0.5~1.5의 비율로 혼합하여 사용할 수 있으며, 바람직하게는 1:1:1로 혼합하여 사용할 수 있다.
The composition of the present invention may include all of streptomycin sulfate, sulfamethoxazole, trimethoprim, tranexamic acid, chloramphenicol, palate, sweet pepper, and pyrazic acid. In this case, the treatment rate of cattle diarrhea is fast, the cure rate is as high as 100%, and the disease is not recurred. When the composition of the present invention includes all three herbal formulas of Oriental herbal medicine, Oriental herbal medicine and Pyric acid, the composition may be mixed and used in a ratio of 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5, Can be mixed in a ratio of 1: 1: 1.
본 발명의 조성물을 적용시킬 수 있는 가축은 인간이 사육할 수 있는 모든 동물을 포함할 수 있으며, 예를 들면 소, 돼지, 닭, 오리 및 양 등이 가능하며, 바람직하게는 소이다. 본 발명의 조성물은 가축의 설사질환 치료 및 예방에 광범위하게 적용될 수 있는데, 바람직하게는 소의 설사질환, 가장 바람직하게는 송아지 설사증, 특히 송아지 백리 설사증에 이용될 수 있다. Livestock to which the composition of the present invention can be applied can include all animals that can be raised by humans, for example, cattle, pigs, chickens, ducks, sheep, and the like, preferably cows. The composition of the present invention can be widely applied to the treatment and prevention of livestock diarrheal diseases, preferably to bovine diarrheal disease, most preferably to calf diarrhea, especially calf leprosy diarrhea.
송아지 설사증은 송아지에 보이는 급성 또는 만성 설사를 총징하는 것으로, 다양한 바이러스 및 세균 감염, 예들 들어, 로타 바이러스, 코로나 바이러스, 대장균 및 콕시듐 등의 병원성 미생물의 감염에 의해 발생되는 설사질환을 모두 포함하는 개념이다.Calf Diarrhea is a concept that includes both acute and chronic diarrhea seen in calves and includes diarrheal diseases caused by a variety of viral and bacterial infections, such as rotavirus, coronavirus, pathogenic microorganisms such as E. coli and coccidia to be.
본 발명의 '치료 및 예방'에서 '치료'란 상기 조성물을 투여함으로써 가축의 설사질환과 관련된 모든 질병을 호전시키거나 이롭게 변경하는 모든 행위를 의미하며, '예방'이란 본 발명의 조성물을 투여함으로써 가축의 설사질환을 억제시키거나 발병을 지연하는 모든 행위를 말한다.
In the 'treatment and prevention' of the present invention, 'treatment' refers to all actions that improve or alleviate all diseases related to diarrheal disease of a livestock by administration of the composition. 'Prevention' means administration of the composition of the present invention It refers to all actions that inhibit diarrheal disease or delay the onset of livestock.
본 발명의 가축 설사질환 치료용 복합제 조성물은 약학적으로 허용가능한 담체를 추가로 포함할 수 있으며, 담체와 함께 제제화될 수 있다. The composition for treating diarrheal disease of the present invention may further comprise a pharmaceutically acceptable carrier and may be formulated together with a carrier.
본 발명에서 용어, "약학적으로 허용가능한 담체"란 생물체를 자극하지 않고 투여 화합물의 생물학적 활성 및 특성을 저해하지 않는 담체 또는 희석제를 말한다. As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not irritate the organism and does not interfere with the biological activity and properties of the administered compound.
본 발명의 상기 조성물은 본 발명의 화합물, 즉, 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산을 포함하는 캡슐에 부형제 없이 충전하거나 미립화된 고체 담체, 액체 담체 또는 그 양자와 균일하게 충분히 접촉시켜 제조될 수 있으며, 필요한 경우 생성물을 바람직한 제제로 성형하여 사용할 수 있다. 적합한 담체 부형제의 예로서 전분, 물, 식염수, 에탄올, 글리세롤, 링거액 및 덱스트로스 용액 등을 들 수 있으며, 문헌(Remington`s Pharmaceutical Science, 19thEd., 1995, Mack Publishing Company, Easton PA)등에 개시되어 있는 바에 따라 당해 기술 분야에 알려진 적합한 제제로 제제화할 수 있다. The composition of the present invention may be formulated in a capsule comprising a compound of the present invention, i. E., Streptomycin sulfate, sulfamethoxazole, trimethoprim, and tranexamic acid, in the form of a solid or solid carrier, , And if necessary, the product can be molded into a desired formulation and used. And as examples of excipients suitable carriers include starch, water, saline, ethanol, glycerol, Ringer's solution and dextrose solution or the like, the literature (Remington`s Pharmaceutical Science, 19 th Ed., 1995, Mack Publishing Company, Easton PA), etc. May be formulated into suitable formulations known in the art as disclosed herein.
발명의 복합제 화합물은 전체 조성물 총 중량에 대하여 0.0001 ~ 99 중량%, 바람직하게는 50 ~ 80 중량%의 양으로 포함되어 제제화될 수 있다. 이때, 조성물에 포함되는 각 화합물은 건조분말 중량을 기준으로, 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산이 8~12 : 4~8 : 1~2 : 2~3의 중량비로 포함되는 것이 바람직하며, 가장 바람직하게는 10 : 6 : 1.2 : 2.5의 중량비로 포함되어 제제화된다.
The complex compound of the present invention may be formulated in an amount of 0.0001 to 99% by weight, preferably 50 to 80% by weight, based on the total weight of the total composition. At this time, each compound contained in the composition is added at a weight ratio of 8 to 12: 4 to 8: 1 to 2: 2 to 3, based on the dry powder weight, of streptomycin sulfate, sulfamethoxazole, trimethoprim and tranexamic acid , Most preferably in a weight ratio of 10: 6: 1.2: 2.5.
또한, 본 발명의 상기 조성물은 이를 유효성분으로 포함하는 어떠한 제형으로도 적용가능하며, 경구용 또는 비경구용 제형으로 제조할 수 있다. 본 발명의 약학적 제형은 구강(oral), 직장(rectal), 비강(nasal), 국소(topical; 볼 및 혀 밑을 포함), 피하, 질(vaginal) 또는 비경구(parenteral; 근육내, 피하 및 정맥내를 포함) 투여에 적당한 것 또는 흡입(inhalation) 또는 주입(insufflation)에 의한 투여에 적당한 형태를 포함한다. In addition, the composition of the present invention can be applied to any formulation containing it as an active ingredient and can be manufactured into oral or parenteral formulations. The pharmaceutical formulations of the present invention may be administered orally, rectally, nasal, topical (including under the ball and tongue), subcutaneous, vaginal or parenteral (intramuscular, subcutaneous And intravenous), or forms suitable for administration by inhalation or insufflation.
본 발명의 조성물을 유효성분으로 포함하는 경구 투여용 제형으로는, 예를 들어 정제, 트로키제, 로렌지, 수용성 또는 유성현탁액, 조제분말 또는 과립, 에멀젼, 하드 또는 소프트 캡슐, 시럽 또는 엘릭시르제로 제제화할 수 있다. 정제 및 캡슐 등의 제형으로 제제화하기 위해, 락토오스, 사카로오스, 솔비톨, 만니톨, 전분, 아밀로펙틴, 셀룰로오스 또는 젤라틴과 같은 결합제, 디칼슘 포스페이트와 같은 부형제, 옥수수 전분 또는 고구마 전분과 같은 붕괴제, 스테아르산 마그네슘, 스테아르산 칼슘, 스테아릴푸마르산 나트륨 또는 폴리에틸렌글리콜 왁스와 같은 윤활유를 포함할 수 있으며, 캡슐제형의 경우 상기 언급한 물질 외에도 지방유와 같은 액체 담체를 더 함유할 수 있다.Examples of formulations for oral administration comprising the composition of the present invention as an active ingredient include tablets, troches, lozenges, aqueous or oily suspensions, prepared powders or granules, emulsions, hard or soft capsules, syrups or elixirs can do. A binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin, an excipient such as dicalcium phosphate, a disintegrating agent such as corn starch or sweet potato starch, a disintegrant such as magnesium stearate , Calcium stearate, sodium stearyl fumarate or polyethylene glycol wax. In the case of a capsule formulation, in addition to the above-mentioned materials, a liquid carrier such as a fatty oil may be further contained.
본 발명의 조성물을 유효성분으로 포함하는 비경구 투여용 제형으로는, 피하주사, 정맥주사 또는 근육내 주사 등의 주사용 형태, 좌제 주입방식 또는 호흡기를 통하여 흡입이 가능하도록 하는 에어로졸제 등 스프레이용으로 제제화할 수 있다. 주사용 제형으로 제제화하기 위해서는 본 발명의 조성물을 안정제 또는 완충제와 함께 물에서 혼합하여 용액 또는 현탁액으로 제조하고, 이를 앰플 또는 바이알의 단위 투여용으로 제제화할 수 있다. 좌제로 주입하기 위해서는, 코코아버터 또는 다른 글리세라이드 등 통상의 좌약 베이스를 포함하는 좌약 또는 체료 관장제와 같은 직장투여용 조성물로 제제화할 수 있다. 에어로졸제 등의 스프레이용으로 제형화하는 경우, 수분산된 농축물 또는 습윤 분말이 분산되도록 추진제 등이 첨가제와 함께 배합될 수 있다.
Examples of the formulations for parenteral administration containing the composition of the present invention as an active ingredient include injection forms such as subcutaneous injection, intravenous injection or intramuscular injection, suppository injection method, or aerosol agent for inhalation through a respirator . ≪ / RTI > For formulation into injectable formulations, the compositions of the present invention may be formulated as solutions or suspensions in water with stabilizers or buffers in water, and formulated for unitary administration of ampoules or vials. For injection into suppositories, it may be formulated into rectal compositions such as suppositories or enema preservatives, including conventional suppository bases such as cocoa butter or other glycerides. When formulated for spraying, such as an aerosol formulation, a propellant or the like may be formulated with the additive such that the water-dispersed concentrate or wet powder is dispersed.
또 다른 양태로서, 본 발명은 상기한 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산을 포함하는 가축 설사질환 치료용 복합제 조성물을 투여하는 단계를 포함하는, 가축 설사질환의 치료방법에 관한 것이다. In another aspect, the present invention relates to a method for the treatment of livestock diarrheal disease comprising the step of administering a combination composition for treating livestock diarrhea disease comprising streptomycin sulfate, sulfamethoxazole, trimethoprim and tranexamic acid as described above .
본 발명에서 용어, "투여"는 어떠한 적절한 방법으로 가축에게 본 발명의 약제학적 조성물을 도입하는 것을 의미하며, 본 발명의 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 경구 또는 비경구의 다양한 경로를 통하여 투여될 수 있으며, 구체적으로, 구강, 직장, 국소, 정맥내, 복강내, 근육내, 동맥내, 경피, 비측내, 흡입, 안구 내 또는 피내경로를 통해 통상적인 방식으로 투여될 수 있다. 바람직하게는 경구 투여한다. The term "administering" in the present invention means introducing the pharmaceutical composition of the present invention to a livestock in any appropriate manner, and the route of administration of the composition of the present invention may be various routes of oral or parenteral routes And can be administered in a conventional manner via oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, intranasal, inhalation, ocular or intradermal routes . Preferably, it is orally administered.
본 발명의 치료방법은 상기 화합물을 약학적 유효량으로 투여하는 것을 포함한다. 적합한 총 1일 사용량은 올바른 의학적 판단범위 내에서 처치의에 의해 결정될 수 있다. 특정 가축에 대한 구체적인 치료적 유효량은 달성하고자 하는 반응의 종류와 정도, 경우에 따라 다른 제제가 사용되는지의 여부를 비롯한 구체적 조성물, 가축의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 구체적 조성물과 함께 사용되거나 동시 사용되는 약물을 비롯한 다양한 인자와 의약 분야에 잘 알려진 유사 인자에 따라 다르게 적용하는 것이 바람직하다. 따라서, 본 발명의 화합물의 바람직한 투여량은 전술한 사항을 고려하여 결정할 수 있으며, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 화합물은 0.0001 내지 1000mg/kg, 바람직하게는 0.01~200mg/kg의 양을 일일 1회 내지 수회로 나누어 투여할 수 있다. 개체를 기준으로 한 바람직한 투여량은 한 개체당 복합제 총 중량을 기준으로 1500 내지 6000 mg의 양을 1일 1회 내지 3회에 걸쳐 투여할 수 있다. 본 발명의 복합제 조성물의 투여는 단일 복합제로 제제화된 약학적 조성물을 투여하는 것 외에, 각 구성물질을 각각 제제화한 후 동시에 투여하는 것을 포함하는 개념이다. The method of treatment of the present invention comprises administering the compound in a pharmaceutically effective amount. The appropriate total daily dose may be determined by the practitioner within the scope of appropriate medical judgment. The specific therapeutically effective amount for a particular animal will depend on the type and extent of the response to be achieved, the specific composition including whether or not other agents are used, the age, weight, general health status, sex and diet of the animal, The route of administration and the fraction of the composition, the duration of the treatment, the drugs used or co-used with the specific composition, and the like, well known in the medical arts. Accordingly, the preferable dosage of the compound of the present invention can be determined in view of the above-mentioned matters, and can be appropriately selected by those skilled in the art. However, for a desired effect, the compound of the present invention may be administered in an amount of 0.0001 to 1000 mg / kg, preferably 0.01 to 200 mg / kg, once to several times per day. Preferred dosages on an individual basis may be administered in an amount of 1500 to 6000 mg, once per day to 3 times per day, based on the total weight of the compound per individual. The administration of the combination composition of the present invention includes not only administering a pharmaceutical composition formulated with a single combination agent, but also separately administering each of the constituent substances after formulation.
추가로 궁귀교애탕, 향사평위산 및 평위산 등의 한방처방생약을 함께 투여할 수 있으며, 과립분말형태의 한방처방생약을 사용하는 경우 생약의 1회 사용량은 각각 3~10g 일 수 있고, 이러한 용량을 하루 3회 처방하여 투여할 수 있다.In addition, when herbal medicine herbal medicine such as royal guinea herbal medicine, oriental herbal medicine and pyrijisan herbal medicine can be administered together, herbal medicine can be used at a dosage of 3 ~ 10g each when granular powder type herbal medicine is used. The dose can be administered three times a day.
또한, 본 발명의 조성물은 가축 설사질환의 치료 및 예방을 위하여 단독으로 사용하거나, 수술, 호르몬 치료, 약물 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.
In addition, the composition of the present invention can be used alone for the treatment and prevention of livestock diarrheal disease, or in combination with methods using surgery, hormone therapy, drug therapy, and biological response modifier.
이하, 본 발명의 바람직한 실시예를 통해 본 발명의 구성 및 작용을 더욱 상세히 설명하기로 한다. 다만, 하기 실시예는 본 발명의 이해를 돕기 위한 것으로, 본 발명의 범위가 하기 실시예에 한정되지는 않는다. 여기에 기재되지 않은 내용은 이 기술 분야에서 숙련된 자이면 충분히 기술적으로 유추할 수 있는 것이므로 그 설명을 생략하기로 한다.
Hereinafter, the configuration and operation of the present invention will be described in more detail with reference to preferred embodiments of the present invention. However, the following examples are provided to aid understanding of the present invention, and the scope of the present invention is not limited to the following examples. The contents not described here are sufficiently technically inferior to those skilled in the art, and a description thereof will be omitted.
실시예1. 가축 설사질환 치료용 복합제의 항균 활성 평가Example 1. Evaluation of Antimicrobial Activity of Combination Agent for Treatment of Livestock Diarrhea
복합제의 항균 활성을 확인하기 위해 디스크확산법에 의한 검사를 실시하였다. 하기 표 1의 조성으로 구성성분을 혼합하여 각 복합제를 제조한 후, 대장균에 대한 항균 활성을 조사하였다. 각 복합제는 각 화합물을 중량 기준으로 하기 표 1에 기재된 조성비로 혼합한 후, 물에 녹여 5% 수용액을 제조하였다.In order to confirm the antimicrobial activity of the combination agent, a disk diffusion test was performed. The components were mixed in the composition shown in Table 1 below to prepare each complex, and the antibacterial activity against E. coli was examined. Each compound was mixed in a composition ratio shown in Table 1 on a weight basis, and then dissolved in water to prepare a 5% aqueous solution.
뮬러 힌톤 아가(Muller Hinton Agar ; Difco. USA) 배지를 4㎜ 두께로 배양 용기에 붓고 실온으로 식혔다. 대장균(E.coli) 및 살모넬라균(Salmonella typhimurium)을 트립티카제 소이 아가(Trypticase Soy Agar)에 선상도말하여 18시간 배양 후, 단일 콜로니를 루프(loop)로 떼어 4㎖의 멸균식염수에 현탁하고, 0.5 맥팔랜드 표준(McFarland standard)에 해당하는 O.D(OpticalDensity) 값으로 조절하였다. 멸균된 면봉으로 균을 배지 표면에 도말하고 5분 정도 건조하였다.Muller Hinton Agar (Difco, USA) medium was cultured to a thickness of 4 mm Poured into containers and cooled to room temperature. E. coli and Salmonella typhimurium were cultured for 18 hours on a Trypticase Soy Agar and then a single colony was loosely separated and suspended in 4 ml of sterilized saline And adjusted to OD (Optical Density) value corresponding to 0.5 McFarland standard. The bacteria were spread on the surface of the medium with a sterilized cotton swab and dried for about 5 minutes.
복합제 시료는 사용전 0.2㎛ 주사기형 필터로 여과하여 각각 60㎕ 씩 직경 10㎜의 멸균된 페이퍼디스크(Paper disk ; Advantec, Japan)에 흡수시키고 30분간 방치 후, 36℃에서 18시간 배양하고 클리어존(clear zone)의 지름을 측정하였으며, 그 결과를 하기 표 1에 나타내었다.The complex sample was filtered with a 0.2 탆 syringe filter before use, absorbed into paper disks (Advantec, Japan) sterilized with a diameter of 10 mm by 60 쨉 l each, allowed to stand for 30 minutes, cultured at 36 캜 for 18 hours, and the diameter of the clear zone was measured. The results are shown in Table 1 below.
*대조군 - 생리식염수
*복합제1 - (10 : 6 : 1.2 : 2.5)
*복합제2 - (6 : 10 : 1.2 : 2.5)
*복합제3 - (10 : 2 : 2.4 : 2.5)
*복합제4 - (5 : 5 : 1.2 : 2.5)
*복합제5 - (10 : 0 : 0 : 2.5)
*복합제6 - (0 : 6 : 1.2 : 2.5)
*단일제1 - 황산스트렙토마이신
*단일제2 - 설파메톡사졸Formulation - (Streptomycin sulfate: Sulfamethoxazole: Trimethoprim: Tranexamic acid)
* Control - saline solution
* Compound 1 - (10: 6: 1.2: 2.5)
Composite 2 - (6: 10: 1.2: 2.5)
Composite 3 - (10: 2: 2.4: 2.5)
Composite 4 - (5: 5: 1.2: 2.5)
* Compound 5 - (10: 0: 0: 2.5)
Composite 6 - (0: 6: 1.2: 2.5)
* Single-product 1-sulfate streptomycin
* Single 2-sulfamethoxazole
표 1에서 보듯이, 본 발명의 복합제 조성물은 각 구성성분의 조성비에 따라 항균활성에 차이를 나타냈으며, 단일제에 비해 복합제의 항균 활성이 높았으며, 복합제 중 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산이 8~12 : 4~8 : 1~2 : 2~3의 중량비 범위, 특히, 10 : 6 : 1.2 : 2.5 비율일 때, 항균 활성이 높은 것을 확인할 수 있었다.
As shown in Table 1, the composite composition of the present invention exhibited a difference in antibacterial activity depending on the composition ratio of each component, and the antibacterial activity of the combination agent was higher than that of the single agent. In the combination agent, It was confirmed that the antimicrobial activity was high when the ratio of primate and tranexamic acid was 8 to 12: 4 to 8: 1 to 2: 2 to 3, particularly 10: 6: 1.2: 2.5.
실시예2. 경구투여용 복합제 제조Example 2. Manufacture of complex for oral administration
가축 설사질환 치료를 위한 경구투여용 복합제를 제조하였다.An oral dosage form combination for the treatment of livestock diarrheal disease was prepared.
실시예1의 제제(복합제1~복합제6, 단일제1, 단일제2) 조성비와 동일하게 각 복합제를 분말 상태로 혼합한 후, 약제학적 부형제를 첨가하여 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다. 각 복합제의 구성 성분 함량은 하기 표 2와 같다.Each of the complexes was mixed in powder form in the same manner as the composition ratios of the preparations of Example 1 (Composites 1 to 6, 1, and 2), followed by addition of pharmaceutical excipients and tableting according to a conventional preparation method. . The components of each combination agent are shown in Table 2 below.
실시예 3. 복합제의 설사 억제 시험Example 3 Diarrhea Suppression Test of Compound
최근 1 ~ 2년간 송아지 설사증이 발생하여 상재하고 있는 경기도 소재의 농장에서 선발된 10~20일령의 송아지(50~60kg)를 대상으로 설사 증상을 나타내는 송아지 80두를 선별하였다. Eighty calves with diarrhea were selected from 10 ~ 20 day old calves (50 ~ 60kg) selected from farms in Gyeonggi province where calf diarrhea occurred for the past 1 ~ 2 years.
상기 실시예 2에서 제조한 경구투여용 복합제를 설사 증상을 나타내는 송아지에 1일 3회에 걸쳐 각 제제를 투여하였다.(설사 증상을 나타낸 날로부터 3일 이내에 투여를 개시하였으며, 한 가지 제제 당 10마리씩 그룹화하여 투여하였으며, 제제 별로 평균값을 산출하였다.) 3일 및 5일째 설사 억제 효과(약함 0→10 강함)를 조사하여 하기 표 3에 기재하였다.The compound for oral administration prepared in Example 2 was administered to the calf showing diarrhea symptoms three times a day, three times per day (the administration was started within 3 days from the day on which the diarrhea symptoms were shown, and 10 The results are shown in Table 3 below. [Table 3] < EMI ID = 18.1 > < tb > < TABLE >
표 3에서 보듯이, 본 발명의 복합제제는 설사 억제 효과를 내며, 단일제에 비해 복합제의 설사 억제능이 높았으며, 복합제 중 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산이 8~12 : 4~8 : 1~2 : 2~3의 중량비 범위, 특히, 10 : 6 : 1.2 : 2.5 비율일 때, 가장 높은 설사 억제 효과를 내는 것을 확인할 수 있었다.
As shown in Table 3, the combination preparation of the present invention had a diarrhea suppressing effect, and the diarrhea suppressing ability of the combination agent was higher than that of the single agent. In the combination agent, streptomycin sulfate, sulfamethoxazole, trimethoprim, : 4 to 8: 1 to 2: 2 to 3, and particularly 10: 6: 1.2: 2.5 ratio, the highest diarrhea suppressing effect was obtained.
실시예 4. 체중 증가량 및 폐사율 비교Example 4. Comparison of weight gain and mortality
실시예 3의 실험 진행과 함께, 투약개시일로부터 3, 7, 10일째 되는 날 이들 송아지의 체중 증가량 및 폐사율(각 투여 그룹별로 10마리 중 폐사한 마리수)을 조사하였다.With the progress of the experiment of Example 3, the body weight gain and mortality of these calves (one dead animal out of 10 animals per each administration group) were examined on the days 3, 7, and 10 from the start of administration.
표 4에서 보듯이, 단일제에 비해 복합제를 투여한 송아지의 체중 증가량이 높았으며, 복합제 중 황산스트렙토마이신, 설파메톡사졸, 트리메토프림 및 트라넥사민산이 8~12 : 4~8 : 1~2 : 2~3의 중량비 범위, 특히, 10 : 6 : 1.2 : 2.5 비율일 때, 가장 높은 체중 증가량을 나타냈으며, 폐사율이 극히 낮은 것을 확인할 수 있었다.
As shown in Table 4, the weight gain of the calf administered with the combination agent was higher than that of the single agent, and the weight of the combination of streptomycin sulfate, sulfamethoxazole, trimethoprim and tranexamic acid was 8-12: 4 to 8: : The highest weight gain was observed in the weight ratio range of 2 to 3, particularly in the ratio of 10: 6: 1.2: 2.5, and the mortality rate was extremely low.
실시예 5. 한방처방생약 추가 투여시 송아지 백리 치료 효과 및 재발율 조사Example 5. Investigation of the effect and recurrence rate of calf bark treatment in addition to herbal medicine prescribed herbal medicine
상기 실시예 3~4 결과를 통해 송아지 설사증 치료 효과가 가장 높은 것으로 나타난 복합제1과 함께 한방처방생약(궁귀교애탕, 향사평위산 및 평위산)을 추가로 투여한 경우 치료 속도 및 병의 재발율을 비교하였다.The results of Examples 3 to 4 show that the treatment of calf diarrhea with the highest dose of Compound 1 and the recurrence rate of the herbal medicine, Respectively.
송아지 백리 설사증을 나타내고 있는 10~30일령의 송아지를 대상으로 투여하였으며, 투여제 조성에 따라 20마리씩 그룹화하여 조사하였으며, 1일 3회에 걸쳐 각 제제를 투여하였다. 설사 증상을 나타낸 날로부터 3일 이내에 투여를 개시하였다. 10 to 30 days old calves showing calf bark diarrhea were administered to each group. Twenty calves were grouped according to the dosage composition, and each preparation was administered three times a day. The administration was started within 3 days from the day of the diarrhea symptom.
투약 그룹별로 투약시점부터 설사증이 완치되는 시점까지 시간을 측정한 후 평균내어 치료 속도를 조사하였고, 완치 후 설사증 재발여부를 조사하여 재발율을 조사하였다.We measured the time from the time of medication to the time of complete recovery of diarrhea, and the rate of treatment was measured. The recurrence rate was examined by investigating the recurrence of diarrhea after cure.
* 한방처방생약으로서 과립분말 형태의 궁귀교애탕, 향사평위산, 평위산을 준비하였다.* Oriental herb medicine as a granular powder in the form of royal japonggangang, oriental pyeonyasan, pyeongyansan was prepared.
투약 1 - 복합제 1Medication 1 - Compound 1
투약 2 - 복합제 1 + 궁귀교애탕 5g + 향사평위산 5g + 평위산 5gDosage 2 - Combination 1 + Gujanggyoang 5g + Incense Pyongyang 5g + Pyongyang 5g
투약 3 - 복합제 1 + 클로람페니콜 500mg + 궁귀교애탕 5g + 향사평위산 5g + 평위산 5gDosage 3 - Combination 1 + Chloramphenicol 500mg + Palatinate egg yolk 5g + Incense Pyrethane 5g + Pyrethane 5g
투약 4 - 복합제 1 + 평위산 5gMedication 4 - Complex 1 + Pyongyang 5g
투약 5 - 복합제 1 + 판크레아틴(양약 소화제) 500mg
Medication 5 - Combination 1 + Pancreatin (Herbal Extinguishing Agent) 500mg
상기 표 5에서 보듯이, 복합제 1과 함께 과립분말 형태의 궁귀교애탕, 향사평위산, 평위산을 각 5씩 추가로 투여한 경우(투약 2,3) 복합제 1만을 투여한 경우(투약 1)에 비해 설사증 개선 속도가 증진되었으며, 병의 재발율이 현저하게 줄어드는 것을 확인하였다. 도 1에 투약 3 그룹 중 일부 송아지의 치료 성적서를 나타내었다.As shown in the above Table 5, in the case of additionally administering 5 gangguygganggang, oriental pyruvic acid and pyrazic acid in the form of granular powder together with combination agent 1 (dosing 2,3) , The rate of diarrhea improvement was improved and the recurrence rate of the disease was remarkably reduced. Figure 1 shows the therapeutic results of some calves in group 3 of the medication.
Claims (7)
Wherein the composition comprises streptomycin sulfate, sulfamethoxazole, trimethoprim, and tranexamic acid.
The method according to claim 1, wherein the streptomycin sulfate, sulfamethoxazole, trimethoprim and tranexamic acid are contained in a weight ratio of 8-12: 4-8: 1-2: 2-3. A combination composition for treating diseases.
The combination composition for treating diarrheal disease according to claim 1 or 2, wherein the composition further comprises chloramphenicol.
3. The combination composition for treating diarrheal disease according to claim 1 or 2, wherein the composition further comprises at least one herbal medicine selected from Oriental herb tea, oriental pyruvic acid and pyruvic acid.
4. The combination composition for treating diarrheal disease according to claim 3, wherein the composition further comprises one or more oriental herbal medicine selected from the group consisting of arthropods, angelic pyruvic acid and pyruvic acid.
The combination composition of claim 1, wherein the diarrheal disease is calf diarrhea.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150115572A KR102619907B1 (en) | 2015-08-17 | 2015-08-17 | Combination composition for treatment of diarrhea in calf |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150115572A KR102619907B1 (en) | 2015-08-17 | 2015-08-17 | Combination composition for treatment of diarrhea in calf |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170021140A true KR20170021140A (en) | 2017-02-27 |
| KR102619907B1 KR102619907B1 (en) | 2024-01-02 |
Family
ID=58315949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150115572A KR102619907B1 (en) | 2015-08-17 | 2015-08-17 | Combination composition for treatment of diarrhea in calf |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102619907B1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100936439B1 (en) * | 2009-06-12 | 2010-01-12 | 서화수 | Combination composition for treatment of canine parvovirus infection |
| JP2011519952A (en) * | 2008-05-07 | 2011-07-14 | サリックス ファーマシューティカルズ リミテッド | Method of treating bowel disease by administration of intestinal cleanser and antibiotics |
| JP2013234175A (en) * | 2012-04-11 | 2013-11-21 | Daiichi Sankyo Healthcare Co Ltd | Anti-rotavirus agent |
| KR101400791B1 (en) * | 2012-10-04 | 2014-05-29 | 주식회사대성미생물연구소 | Functional antibiotic complex composition for animal use |
-
2015
- 2015-08-17 KR KR1020150115572A patent/KR102619907B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011519952A (en) * | 2008-05-07 | 2011-07-14 | サリックス ファーマシューティカルズ リミテッド | Method of treating bowel disease by administration of intestinal cleanser and antibiotics |
| KR100936439B1 (en) * | 2009-06-12 | 2010-01-12 | 서화수 | Combination composition for treatment of canine parvovirus infection |
| JP2013234175A (en) * | 2012-04-11 | 2013-11-21 | Daiichi Sankyo Healthcare Co Ltd | Anti-rotavirus agent |
| KR101400791B1 (en) * | 2012-10-04 | 2014-05-29 | 주식회사대성미생물연구소 | Functional antibiotic complex composition for animal use |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102619907B1 (en) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5478579A (en) | Method for treatment of osteoporosis | |
| CN103704513B (en) | Feed for treating swine plague and preparation method thereof | |
| CN104257844B (en) | A kind of Chinese powder medicine treating porcine hyperthermia and preparation technology thereof | |
| CN101934070A (en) | Veterinary antibacterial drug composition containing lysozyme and oligosaccharide and application thereof | |
| CN101926818A (en) | Medicine composition containing tea polyphenol and alginic acid and application thereof | |
| US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
| KR101067536B1 (en) | medical's a composite of the calf | |
| CN105832759B (en) | A pharmaceutical composition for preventing and/or treating diseases caused by coronavirus and/or rotavirus | |
| CN101244164A (en) | Medicament for preventing and treating hydropsy of pigling | |
| Zeenat et al. | An appraisal of medicinal properties of Shibb-e-Yamani (Alum): a review | |
| KR20170021140A (en) | Combination composition for treatment of diarrhea in calf | |
| US20240180994A1 (en) | Herbal extract formula for treating coronavirus infection | |
| KR100936439B1 (en) | Combination composition for treatment of canine parvovirus infection | |
| CN105878227A (en) | Pharmaceutical composition for treating staphylococcus aureus infection | |
| CN103719552B (en) | Feed for preventing and treating swine erysipelas and preparation method for feed | |
| JP4610730B2 (en) | Composition for calcium supplementation | |
| JP2002265354A (en) | Anti-helicobacter pylori agent composition | |
| JPH01172330A (en) | Preventive and remedy for infectious disease of salmonella typhimurium of mammals and birds | |
| CN114099493B (en) | Active compound for inhibiting insulin resistance and application thereof | |
| KR20170021139A (en) | Composition comprising western and oriental medicine for treatment of canine parvovirus infection | |
| US20080145409A1 (en) | Composition for the treatment and prevention of peptic ulcer | |
| KR101779513B1 (en) | Pharmaceutical composition comprising the isopropanol extract of artemisia | |
| RU2709144C1 (en) | Method for treating dyspepsia of calves | |
| RU2426531C1 (en) | Liquid water pharmaceutical composition of ambroxol and pharmaceutical preparation based on it, intended for treating diseases of respiratory ways with formation of viscous sputum (versions) | |
| Chang et al. | Activity of roxithromycin against Toxoplasma gondii in murine models |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |